tetano
Editor, Senior Moderator
Pharmacoepidemiol Drug Saf. 2017 Nov 20. doi: 10.1002/pds.4347. [Epub ahead of print]
[h=1]Observational safety study of specific outcomes after trivalent cell culture seasonal influenza vaccination (Optaflu? ) among adults in THIN database of electronic UK primary healthcare records.[/h] Hall GC[SUP]1[/SUP], Davies PTG[SUP]2[/SUP], Karim MY[SUP]3[/SUP], Haag MDM[SUP]4[/SUP], O'Leary C[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE:[/h] To investigate the safety of trivalent seasonal influenza vaccine (TIVc) (Optaflu[SUP]?[/SUP] ), the first cell culture seasonal trivalent influenza vaccine available in Europe.
[h=4]METHODS:[/h] Codes and unstructured text in adult electronic healthcare records (The Health Improvement Network) were searched for a TIVc brand name or batch number and possible outcomes within a 3 month pre- to 6 month post-TIVc exposure study period (2012-2015). The outcomes were severe allergic reactions, Bell's palsy, convulsions, demyelination, paresthesia, noninfectious encephalitis, neuritis (optic and brachial), vasculitis, inflammatory bowel disease, and thrombocytopenia. Risk periods were defined based on biologically plausible time frame postvaccination when an outcome caused by the vaccine might be expected to occur. Possible outcomes were adjudicated against outcome specific case definitions and a date of onset assigned by using electronic and other medical records. Observed (risk period) to expected (outside risk and preexposure periods) rate ratios, postexposure incidence, and plots of time from exposure to outcome were reported.
[h=4]RESULTS:[/h] Sixteen of 1011 events from 4578 exposures fulfilled a primary case definition and had a date of onset during the study period. Three were in observed time. The observed-to-expected rate ratios were (3.3, 95% CI 0.3, 31.7) for convulsions and (1.5, 95% CI 0.2, 14.9) for thrombocytopenia with 1 outcome each in observed time. There was 1 incident inflammatory bowel disease in observed, but none in expected, time.
[h=4]CONCLUSION:[/h] The small sample size restricts interpretation; however, no hypothesis of an increased risk of a study outcome was generated. Adjudication of events against case definitions to reduce misclassification of onset and outcomes allowed use of precise risk periods. KEY POINTS This observational study did not generate a hypothesis of an association between the first cell-culture seasonal influenza vaccination available in the European Union and any of the study outcomes (severe allergic reactions, Bell's palsy, convulsions, demyelination, paresthesia, noninfectious encephalitis, neuritis [optic and brachial], vasculitis, inflammatory bowel disease [IBD], and thrombocytopenia). The small sample size limits interpretation of the results. The review of each possible outcome identified from electronic healthcare records against case definitions was included to minimize misclassification of time and outcomes and allow the use of precise risk-periods in an observed-to-expected within cohort analysis. Plots of time from exposure to outcome were included to assess the risk windows.
Copyright ? 2017 John Wiley & Sons, Ltd.
[h=4]KEYWORDS:[/h] Bell's palsy; anaphylaxis; convulsions; inflammatory bowel disease; influenza; paresthesia; pharmacoepidemiology; safety; thrombocytopenia; vaccination; vasculitis
PMID: 29152808 DOI: 10.1002/pds.4347
[h=1]Observational safety study of specific outcomes after trivalent cell culture seasonal influenza vaccination (Optaflu? ) among adults in THIN database of electronic UK primary healthcare records.[/h] Hall GC[SUP]1[/SUP], Davies PTG[SUP]2[/SUP], Karim MY[SUP]3[/SUP], Haag MDM[SUP]4[/SUP], O'Leary C[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE:[/h] To investigate the safety of trivalent seasonal influenza vaccine (TIVc) (Optaflu[SUP]?[/SUP] ), the first cell culture seasonal trivalent influenza vaccine available in Europe.
[h=4]METHODS:[/h] Codes and unstructured text in adult electronic healthcare records (The Health Improvement Network) were searched for a TIVc brand name or batch number and possible outcomes within a 3 month pre- to 6 month post-TIVc exposure study period (2012-2015). The outcomes were severe allergic reactions, Bell's palsy, convulsions, demyelination, paresthesia, noninfectious encephalitis, neuritis (optic and brachial), vasculitis, inflammatory bowel disease, and thrombocytopenia. Risk periods were defined based on biologically plausible time frame postvaccination when an outcome caused by the vaccine might be expected to occur. Possible outcomes were adjudicated against outcome specific case definitions and a date of onset assigned by using electronic and other medical records. Observed (risk period) to expected (outside risk and preexposure periods) rate ratios, postexposure incidence, and plots of time from exposure to outcome were reported.
[h=4]RESULTS:[/h] Sixteen of 1011 events from 4578 exposures fulfilled a primary case definition and had a date of onset during the study period. Three were in observed time. The observed-to-expected rate ratios were (3.3, 95% CI 0.3, 31.7) for convulsions and (1.5, 95% CI 0.2, 14.9) for thrombocytopenia with 1 outcome each in observed time. There was 1 incident inflammatory bowel disease in observed, but none in expected, time.
[h=4]CONCLUSION:[/h] The small sample size restricts interpretation; however, no hypothesis of an increased risk of a study outcome was generated. Adjudication of events against case definitions to reduce misclassification of onset and outcomes allowed use of precise risk periods. KEY POINTS This observational study did not generate a hypothesis of an association between the first cell-culture seasonal influenza vaccination available in the European Union and any of the study outcomes (severe allergic reactions, Bell's palsy, convulsions, demyelination, paresthesia, noninfectious encephalitis, neuritis [optic and brachial], vasculitis, inflammatory bowel disease [IBD], and thrombocytopenia). The small sample size limits interpretation of the results. The review of each possible outcome identified from electronic healthcare records against case definitions was included to minimize misclassification of time and outcomes and allow the use of precise risk-periods in an observed-to-expected within cohort analysis. Plots of time from exposure to outcome were included to assess the risk windows.
Copyright ? 2017 John Wiley & Sons, Ltd.
[h=4]KEYWORDS:[/h] Bell's palsy; anaphylaxis; convulsions; inflammatory bowel disease; influenza; paresthesia; pharmacoepidemiology; safety; thrombocytopenia; vaccination; vasculitis
PMID: 29152808 DOI: 10.1002/pds.4347